Infinity to Get $75M Investment, $50M Credit Line from Purdue Nov. 21, 2008 By Catherine Hollingsworth
XTL Shares Nearly Wiped Out After Failed Nerve Pain Study Nov. 19, 2008 By Catherine Hollingsworth XTL Biopharmaceuticals Ltd. said that a Phase II study of its bicifadine for the treatment of diabetic nerve pain did not meet any of its objectives, causing the company's shares to fall 94.4 percent. (BioWorld Today)Read More
